<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00223080</url>
  </required_header>
  <id_info>
    <org_study_id>RV144</org_study_id>
    <secondary_id>HSRRB A-11048</secondary_id>
    <nct_id>NCT00223080</nct_id>
  </id_info>
  <brief_title>HIV Vaccine Trial in Thai Adults</brief_title>
  <official_title>A Phase III Trial of Aventis Pasteur Live Recombinant ALVAC-HIV (vCP1521) Priming With VaxGen gp120 B/E (AIDSVAX B/E) Boosting in HIV-uninfected Thai Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>U.S. Army Medical Research and Materiel Command</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Army Medical Materiel Development Activity</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Armed Forces Research Institute of Medical Sciences, Thailand</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Walter Reed Army Institute of Research (WRAIR)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>MCM Vaccines B.V.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>VaxGen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>The EMMES Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ministry of Health, Thailand</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Royal Thai Army Medical Department</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tripler Army Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Henry M. Jackson Foundation for the Advancement of Military Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>U.S. Army Medical Research and Materiel Command</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether immunizations with an integrated
      combination of ALVAC-HIV (vCP1521) boosted by AIDSVAX gp120 B/E prevent HIV infection in
      healthy Thai volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A vaccine for the prevention of HIV infection remains an urgent need as part of the efforts
      to control the HIV pandemic. In this phase III efficacy trial, a 'prime-boost' vaccine
      strategy is evaluated for prevention of infection and ameliorationn of disease course.
      ALVAC-HIV (vCP1521) from sanofi pasteur is given as the 'prime' vaccine at months 0, 1, 3 and
      6; AIDSVAX gp120 B/E from VaxGen is given as the 'boost' at months 3 and 6. This regimen will
      be given to 8,000 adult Thai subjects, while another 8,000 will be given placebos in a
      double-blinded, randomized manner. Following the completion of each subjects immunization
      phase, he/she will be followed for 3 years with clinic visits every 6 months with HIV
      testing, pre- and post-test counseling. Subjects who become HIV infected will be counseled,
      referred to HIV treatment facilities for management according to national guidelines, and
      offered enrollment in a protocol for extended follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2003</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">July 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HIV infection, assessed every 6 months for 3 years</measure>
    <time_frame>36 Months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16402</enrollment>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>I</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALVAC-HIV vCP1521 + AIDSVAX</intervention_name>
    <description>1cc injected into left deltoid muscle at day 0,weeks 4, 12, 24
Prime/Boost Vaccination</description>
    <arm_group_label>II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALVAC Placebo + AIDSVAX Placebo</intervention_name>
    <description>1cc ALVAC Placebo in left deltoid at day 0 and week 4
1 cc ALVAC Placebo + AIDSVAX Placebo in left deltoid on weeks 12 and 24</description>
    <arm_group_label>I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Thai citizen, 18-30 years of age; either gender,

          -  Available for participation for 3.5 years,

          -  Able to understand study and give written informed consent, Completed enrollment in
             associated screening protocol

        Exclusion Criteria:

          -  HIV positive,

          -  Participant in previous HIV vaccine trial,

          -  Active TB or other systemic disease; immunodeficiency or chronic use of immune
             modifying therapy,

          -  History of anaphylaxis or other serious adverse reactions to vaccines,

          -  For women, breast feeding or pregnant (or planning to become pregnant during the first
             9 months after enrollment)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Supachai Rerks-Ngarm, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ministry of Health, Thailand</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ban Lamung District Hospital</name>
      <address>
        <city>Ban Lamung District</city>
        <state>Chon Buri</state>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phan Tong District Hospital</name>
      <address>
        <city>Phan Tong District</city>
        <state>Chon Buri</state>
        <zip>20160</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sattahip District Hospital</name>
      <address>
        <city>Sattahip District</city>
        <state>Chon Buri</state>
        <zip>20180</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ao Udom Hospital</name>
      <address>
        <city>Sri Racha District</city>
        <state>Chon Buri</state>
        <zip>20230</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ban Chang District Hospital</name>
      <address>
        <city>Ban Chang District</city>
        <state>Rayong</state>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ban Khai District Hospital</name>
      <address>
        <city>Ban Khai District</city>
        <state>Rayong</state>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klaeng District Hospital</name>
      <address>
        <city>Klaeng District</city>
        <state>Rayong</state>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Provincial Health Office</name>
      <address>
        <city>Muang District</city>
        <state>Rayong</state>
        <zip>21000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <link>
    <url>http://www.primeboost3.org/</url>
    <description>Click here for more information about this study: Phase 3 HIV Vaccine Trial in Thai Adults</description>
  </link>
  <reference>
    <citation>Nitayaphan S, Pitisuttithum P, Karnasuta C, Eamsila C, de Souza M, Morgan P, Polonis V, Benenson M, VanCott T, Ratto-Kim S, Kim J, Thapinta D, Garner R, Bussaratid V, Singharaj P, el-Habib R, Gurunathan S, Heyward W, Birx D, McNeil J, Brown AE; Thai AIDS Vaccine Evaluation Group. Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults. J Infect Dis. 2004 Aug 15;190(4):702-6. Epub 2004 Jul 20.</citation>
    <PMID>15272397</PMID>
  </reference>
  <reference>
    <citation>Karnasuta C, Paris RM, Cox JH, Nitayaphan S, Pitisuttithum P, Thongcharoen P, Brown AE, Gurunathan S, Tartaglia J, Heyward WL, McNeil JG, Birx DL, de Souza MS; Thai AIDS Vaccine Evaluation Group, Thailand. Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand. Vaccine. 2005 Mar 31;23(19):2522-9.</citation>
    <PMID>15752839</PMID>
  </reference>
  <reference>
    <citation>Brown AE, Nitayaphan S. Foundations for a Phase III human immunodeficiency virus vaccine trial: A decade of Thai-U.S. Army collaborative research. Mil Med. 2004 Aug;169(8):588-93. Review.</citation>
    <PMID>15379068</PMID>
  </reference>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>September 4, 2012</last_update_submitted>
  <last_update_submitted_qc>September 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV Seronegativity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>October 24, 2016</submitted>
    <returned>December 14, 2016</returned>
    <submitted>June 6, 2017</submitted>
    <returned>December 14, 2017</returned>
    <submitted>December 29, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

